5 citations
,
January 2018 in “Indian Journal of Dermatology/Indian journal of dermatology” This case report describes a 40-year-old woman who developed erythema annulare centrifugum, a type of skin rash, likely triggered by taking the drug aceclofenac.
This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.
5 citations
,
January 2021 in “Journal of Cosmetic Dermatology” This study found that topical cetirizine treatment significantly improved hair regrowth and patient satisfaction in male patients with androgenetic alopecia compared to a placebo, highlighting its potential role in treatment.
July 2022 in “DOAJ (DOAJ: Directory of Open Access Journals)” This article reviews various aspects of androgenetic alopecia, from its historical perceptions to current understanding and treatments, without providing new clinical results.
January 2021 in “Journal of cosmetology & trichology” This study assessed Ageratum conyzoides gel's efficacy in reducing hair loss and improving quality of life in adults with pattern baldness, finding that it decreased temporal recession and improved hair-related distress scores, with a significant reduction in 5α-reductase expression and PGD2 release in vitro.
January 2023 in “Journal of surgery and research” This article discusses various treatments for androgenetic alopecia and reports no new clinical results, noting the condition's aesthetic and psychological impact.
August 2026 in “JAMA Dermatology” This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.
April 2019 in “International research journal of pharmacy” This study found that a 50% ethanolic extract of Adiantum capillus had significant analgesic and anti-inflammatory effects in animals, particularly at the highest tested dose of 300 mg/kg.
5 citations
,
March 2017 in “Journal of Dermatology” This survey reported that 37.6% of male AGA patients were satisfied with their treatments, with the highest satisfaction for 5-alpha-reductase inhibitors, and revealed differing perceptions between physicians and patients about AGA's impact on confidence and treatment involvement.
June 2023 in “Journal of General Procedural Dermatology and Venereology Indonesia” This study explores the risk factors for androgenetic alopecia in women residing in Pasar Ambacang Sub-district, Padang City, emphasizing its potential impact on their quality of life and psychological well-being.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
2 citations
,
January 2025 in “Pharmaceutical Research” This article reviews the possible therapeutic activities of Angelica gigas Nakai root extracts and their components, noting their potential effects on neuro-cognitive, metabolic, and other health conditions, and reports no new clinical results.
This study in a nine-year-old boy from Lebanon identified a gene mutation (c.1066dup p.(Arg356Profs*16)) associated with a rare inborn error of immunity, characterized by craniosynostosis, jaundice, and several other symptoms, expanding the known genotypic and phenotypic spectrum of this condition.
August 2024 in “Quality in Sport” This review article examines the latest understanding of androgenetic alopecia's causes and treatment options, emphasizing current research on alternative treatments beyond the approved medications, finasteride and minoxidil, due to potential side effects and the psychological impact of the condition.
28 citations
,
September 2016 in “Future oncology” In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.
July 2023 in “Research Square (Research Square)” In this study, the application of topical cetirizine 1% once daily for four months in Egyptian male patients with androgenetic alopecia led to a significant increase in terminal hairs and improved hair diversity, with promising safety and efficacy outcomes.
This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.
May 2026 in “Canadian Diabetes & Endocrinology Today” This review discusses the psychosocial impact and potential endocrine implications of androgenetic alopecia, particularly noting a moderate impairment in quality of life, but it reports no new clinical results.
1 citations
,
September 2024 in “Benha Journal of Applied Sciences” This review provides an overview of androgenetic alopecia, detailing its causes, diagnostic methods, and current treatments, noting that combination therapies show promise but newer options like cell-based treatments require more research.
June 2023 in “Trichology and cosmetology:” This study found that 12-week oral supplementation of Ageratum conyzoides extract significantly reduced hairline recession and affected prostaglandin levels in adults with hair loss, though hair density increases were not statistically significant, and no improvements were found in other hair loss measures compared to placebo.
June 2026 in “Journal of Cosmetic Dermatology” This study reported that microneedle-assisted delivery of PEGylated recombinant human fusion collagen significantly improved hair regrowth and density in an androgenetic alopecia mouse model and in a small clinical trial with AGA patients, suggesting potential efficacy and safety for this treatment approach.
135 citations
,
March 2000 in “Journal of Biological Chemistry” This review discusses the roles of the Agouti and Agouti-related proteins in pigmentation and energy regulation and reports no new experimental findings.
23 citations
,
October 2021 in “AAPS PharmSciTech” 8 citations
,
October 2013 in “Der Hautarzt” This article discusses approaches to diagnosing and treating androgenetic alopecia but reports no new clinical results.
September 2023 in “Journal of Cosmetic Dermatology” In a pilot study examining potential treatments for androgenic alopecia, researchers reported that over four months, topical cetirizine 1% improved hair length but not other measures, while diclofenac 3% showed no significant effects, unlike minoxidil, which showed significant improvement across all measured variables.
4 citations
,
May 2020 in “Dermatologic Therapy” In this study, a topical lotion containing Redensyl and Sepicontrol A5 demonstrated effectiveness for treating androgenetic alopecia over 24 weeks, with 73.1% of users seeing moderate improvement and notable increases in hair cycle ratios, alongside enhanced quality of life and satisfaction.
5 citations
,
November 2017 in “Asian journal of pharmaceutical and clinical research” This study found that water fractions of Angiopteris evecta stimulated hair growth in male rabbits, suggesting potential alopecia treatment benefits pending further research in humans.
3 citations
,
November 1999 in “Journal of Cutaneous Medicine and Surgery” AGA is a genetic, hormonal hair loss treated with finasteride, minoxidil, and supplements, but new compounds are being developed.
This study reported that acupuncture combined with topical Aloe vera and celery gel reduced hair loss from alopecia androgenetica after 28 days of treatment.
April 2026 in “International Journal of Molecular Sciences” In this study, Ageratum houstonianum ethanolic extract and its active component agerarin were found to promote hair growth and follicle elongation by increasing SCUBE3 expression via activation of MAPK–AP-1 signaling in human dermal papilla cells, suggesting potential therapeutic value for treating hair loss.